SMTI
Sanara MedTech Inc.
Medical - Instruments & Supplies
Market Cap$170M
5Y Perf.+61.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SMTI vs BDX
Revenue, margins, valuation, and 5-year total return — side by side.
BDX
Becton, Dickinson and Company
Medical - Instruments & Supplies
Market Cap$55.53B
5Y Perf.+3.0%
SMTI vs BDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SMTI | BDX |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $170M | $55.53B |
| Revenue (TTM) | $103M | $21.36B |
| Net Income (TTM) | $-38M | $1.14B |
| Gross Margin | 92.7% | 46.5% |
| Operating Margin | 4.9% | 10.6% |
| Forward P/E | 165.9x | 12.3x |
| Total Debt | $48M | $19.18B |
| Cash & Equiv. | $17M | $851M |
SMTI vs BDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SMTI
BDX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Sanara MedTech Inc. (SMTI) | 100 | 161.0 | +61.0% |
| Becton, Dickinson a… (BDX) | 100 | 103.0 | +3.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SMTI vs BDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BDX leads in 6 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Sanara MedTech Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
SMTI
Sanara MedTech Inc.
The Income Pick
SMTI is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.42
- Rev growth 19.0%, EPS growth -282.5%, 3Y rev CAGR 31.0%
- 218.0% 10Y total return vs BDX's 80.2%
Best for: income & stability and growth exposure
BDX
Becton, Dickinson and Company
The Defensive Pick
BDX carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.66, Low D/E 75.5%, current ratio 1.11x
- Beta 0.66, yield 2.7%, current ratio 1.11x
- Lower P/E (12.3x vs 165.9x)
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SMTI | 19.0% revenue growth vs BDX's 8.2% |
| Value | BDX | Lower P/E (12.3x vs 165.9x) |
| Quality / Margins | BDX | 5.3% margin vs SMTI's -36.4% |
| Stability / Safety | BDX | Beta 0.66 vs SMTI's 1.42, lower leverage |
| Dividends | BDX | 2.7% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | BDX | +51.8% vs SMTI's -40.1% |
| Efficiency (ROA) | BDX | 2.1% ROA vs SMTI's -49.2%, ROIC 4.3% vs 11.8% |
SMTI vs BDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
SMTI vs BDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBDXLAGGINGSMTI
SMTISanara MedTech Inc.
0leads
BDXBecton, Dickinson and…
4leads
6 Total Categories
CATEGORYLEADERvs SMTIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
BDX4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BDX5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
BDX5/6
Risk & VolatilityBeta, volatility, and downside exposure
BDX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SMTI and BDX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 207.2x SMTI's $103M. BDX is the more profitable business, keeping 5.3% of every revenue dollar as net income compared to SMTI's -36.4%. On growth, SMTI holds the edge at +4.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| RevenueTrailing 12 months | $103M | $21.4B |
| EBITDAEarnings before interest/tax | $8M | $4.2B |
| Net IncomeAfter-tax profit | -$38M | $1.1B |
| Free Cash FlowCash after capex | $2M | $3.1B |
| Gross MarginGross profit ÷ Revenue | +92.7% | +46.5% |
| Operating MarginEBIT ÷ Revenue | +4.9% | +10.6% |
| Net MarginNet income ÷ Revenue | -36.4% | +5.3% |
| FCF MarginFCF ÷ Revenue | +2.1% | +14.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.6% | -10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.8% | -2.0% |
Evenly matched — SMTI and BDX each lead in 3 of 6 comparable metrics.
Valuation Metrics
BDX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BDX's 14.7x EV/EBITDA is more attractive than SMTI's 20.3x.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| Market CapShares × price | $170M | $55.5B |
| Enterprise ValueMkt cap + debt − cash | $202M | $73.9B |
| Trailing P/EPrice ÷ TTM EPS | -4.38x | 26.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 165.91x | 12.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.59x |
| EV / EBITDAEnterprise value multiple | 20.27x | 14.65x |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 2.54x |
| Price / BookPrice ÷ Book value/share | 27.75x | 1.73x |
| Price / FCFMarket cap ÷ FCF | 78.85x | 20.80x |
BDX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
BDX leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
BDX delivers a 4.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-179 for SMTI. BDX carries lower financial leverage with a 0.76x debt-to-equity ratio, signaling a more conservative balance sheet compared to SMTI's 8.13x. On the Piotroski fundamental quality scale (0–9), BDX scores 7/9 vs SMTI's 4/9, reflecting strong financial health.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| ROE (TTM)Return on equity | -178.6% | +4.5% |
| ROA (TTM)Return on assets | -49.2% | +2.1% |
| ROICReturn on invested capital | +11.8% | +4.3% |
| ROCEReturn on capital employed | +15.6% | +5.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 8.13x | 0.76x |
| Net DebtTotal debt minus cash | $32M | $18.3B |
| Cash & Equiv.Liquid assets | $17M | $851M |
| Total DebtShort + long-term debt | $48M | $19.2B |
| Interest CoverageEBIT ÷ Interest expense | -9.97x | 4.09x |
BDX leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
BDX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BDX five years ago would be worth $11,693 today (with dividends reinvested), compared to $7,170 for SMTI. Over the past 12 months, BDX leads with a +51.8% total return vs SMTI's -40.1%. The 3-year compound annual growth rate (CAGR) favors BDX at 1.6% vs SMTI's -20.7% — a key indicator of consistent wealth creation.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| YTD ReturnYear-to-date | -17.4% | +0.7% |
| 1-Year ReturnPast 12 months | -40.1% | +51.8% |
| 3-Year ReturnCumulative with dividends | -50.1% | +5.0% |
| 5-Year ReturnCumulative with dividends | -28.3% | +16.9% |
| 10-Year ReturnCumulative with dividends | +218.0% | +80.2% |
| CAGR (3Y)Annualised 3-year return | -20.7% | +1.6% |
BDX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
BDX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than SMTI's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BDX currently trades 74.6% from its 52-week high vs SMTI's 53.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 0.66x |
| 52-Week HighHighest price in past year | $35.95 | $205.52 |
| 52-Week LowLowest price in past year | $16.04 | $100.31 |
| % of 52W HighCurrent price vs 52-week peak | +53.1% | +74.6% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 32.2 |
| Avg Volume (50D)Average daily shares traded | 57K | 2.5M |
BDX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SMTI as "Buy" and BDX as "Buy". Consensus price targets imply 67.7% upside for SMTI (target: $32) vs 12.8% for BDX (target: $173). BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.
| Metric | SMTISanara MedTech In… | BDXBecton, Dickinson… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $32.00 | $172.85 |
| # AnalystsCovering analysts | 3 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $4.17 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.8% |
Insufficient data to determine a leader in this category.
Key Takeaway
BDX leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Best OverallBecton, Dickinson and Compa… (BDX)Leads 4 of 6 categories
Loading custom metrics...
SMTI vs BDX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is SMTI or BDX a better buy right now?
For growth investors, Sanara MedTech Inc.
(SMTI) is the stronger pick with 19. 0% revenue growth year-over-year, versus 8. 2% for Becton, Dickinson and Company (BDX). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Sanara MedTech Inc. (SMTI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SMTI or BDX?
On forward P/E, Becton, Dickinson and Company is actually cheaper at 12.
3x.
03Which is the better long-term investment — SMTI or BDX?
Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.
9%, compared to -28. 3% for Sanara MedTech Inc. (SMTI). Over 10 years, the gap is even starker: SMTI returned +218. 0% versus BDX's +80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SMTI or BDX?
By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.
66β versus Sanara MedTech Inc. 's 1. 42β — meaning SMTI is approximately 115% more volatile than BDX relative to the S&P 500. On balance sheet safety, Becton, Dickinson and Company (BDX) carries a lower debt/equity ratio of 76% versus 8% for Sanara MedTech Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SMTI or BDX?
By revenue growth (latest reported year), Sanara MedTech Inc.
(SMTI) is pulling ahead at 19. 0% versus 8. 2% for Becton, Dickinson and Company (BDX). On earnings-per-share growth, the picture is similar: Becton, Dickinson and Company grew EPS -0. 5% year-over-year, compared to -282. 5% for Sanara MedTech Inc.. Over a 3-year CAGR, SMTI leads at 31. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SMTI or BDX?
Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.
7% net margin versus -36. 4% for Sanara MedTech Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus 7. 1% for SMTI. At the gross margin level — before operating expenses — SMTI leads at 92. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SMTI or BDX more undervalued right now?
On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12.
3x forward P/E versus 165. 9x for Sanara MedTech Inc. — 153. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SMTI: 67. 7% to $32. 00.
08Which pays a better dividend — SMTI or BDX?
In this comparison, BDX (2.
7% yield) pays a dividend. SMTI does not pay a meaningful dividend and should not be held primarily for income.
09Is SMTI or BDX better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, SMTI: +218. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SMTI and BDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SMTI is a small-cap high-growth stock; BDX is a mid-cap quality compounder stock. BDX pays a dividend while SMTI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SMTI: 4.6% · BDX: -10.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.